Trends and variation of treatment of early breast cancer in European certified breast centres: an EUSOMA based analysis

Menée à partir de données multicentriques de la "Société européenne des spécialistes du cancer du sein (EUSOMA)" portant sur 150 150 patientes atteintes d'un cancer du sein de stade précoce, cette étude analyse les tendances et différences concernant la prise en charge de la maladie en Europe

Résumé en anglais

Background: Practice indicators measure provided care making use of real-world data. This study describes trends and variations of adjuvant treatment of early breast cancer (EBC) using the European Society of Breast Cancer Specialists (EUSOMA) database.

Methods: The analysis was conducted on anonymous cumulative data registered by 56 certified breast centres, which all entered at least 500 new diagnoses in the database in the ten-year period 2010-2019. Practice trends of radiotherapy, endocrine treatment, chemotherapy and anti-HER2 therapy were evaluated. The association with age group (<50, 50-69, ≥70) and geographical area of the centre (Northern, Central, Southern Europe; NE, CE, SE) was assessed with the Pearson Chi2 test for independence in contingency tables.

Results: 150,150 patients with EBC were selected. Overall, radiotherapy was administered more frequently in NE centres and conversely endocrine, chemo- and anti-HER2 therapy were used more in SE centres (p<0.001). 46.9% of the pN1 patients received postmastectomy radiotherapy, with significant differences by age and geographical region (p<0.001). Adjuvant endocrine treatment for endocrine sensitive carcinoma in situ was administered in 46.1%, with a decreasing trend during the study period (58.5% to 34.5%; p<0.001). Anti-HER2 therapy was delivered in 75.6% of all patients with HER2BC T1a/bN0, patients older than 70 received anti-HER2 in 67.6% in SE compared to 31.3% in NE centres.

Conclusion: Important variations in EBC management between European certified breast centres have been demonstrated. Practice indicators using real-world data can help to monitor, evaluate and eventually guide and align good clinical practice in the management of breast cancer.